// App-Quantinova.ai

: Deucravacitinib, a Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Psoriasis: Reductions in Individual Component Scores and Body Regions of the Psoriasis Area and Severity Index in the Phase 3 POETYK PSO-1 and PSO-2 Trials

Researchers

Presenter

  • Jeffrey M. Sobell

Principal Investigators

  • Kilian Eyerich

  • Andrew Blauvelt

  • Jennifer Cather

  • Carle Paul

  • Subhashis Banerjee

  • Lauren Hippeli

  • Renata M. Kisa

  • Akimichi Morita

Medical Centers

  • Tufts Medical Center, Boston, MA

  • Karolinska Institutet, Stockholm, Sweden

  • Oregon Medical Research Center, Portland, OR, USA, Portland, OR

  • Mindful Dermatology and Modern Research Associates, Dallas, USA

  • Toulouse University and CHU, Toulouse, France

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Locations

  • United States

  • France

  • United Kingdom

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • N/A

Drug/Treatment

  • Apremilast

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved